Effect of Genetic Polymorphism Including NUP153 and SVEP1 on the Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects - Xiang, Qian; Liu, Zhiyan; Mu, Guangyan; Xie, Qiufen; Zhang, Hanxu; Zhou, Shuang; Wang, Zining; Guo, Ninghong; Huang, Jie; Jiang, Jie; Li, Jian; Yang, Guoping; et al. (Clinical drug investigation, 2022)
Keywords: Adenosine; Adenosine diphosphate; Bioequivalence; Bioinformatics; Blood platelets; Cell Adhesion Molecules; Clinical trials; Drug development; Drug dosages; Gene loci; Genome-Wide Association Study; Humans; Internal Medicine; Intracellular Signaling Peptides and Proteins - pharmacology; Ion Channels; Lectins, C-Type; Medicine; Medicine & Public Health; NCT; NCT03161002; Nuclear Pore Complex Proteins - pharmacology; Nucleotides - pharmacology; Original Research Article; Pharmacodynamics; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Plasma; Platelet Aggregation; Platelet Aggregation Inhibitors; Poly(ADP-ribose) Polymerases - pharmacology; Polymorphism; Polymorphism, Single Nucleotide - genetics; Protein Serine-Threonine Kinases - antagonists & inhibitors; Proto-Oncogene Proteins; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Beijing China; United States--US; China